Mutation takes no vacation: Can structured treatment interruptions increase the risk of drug-resistant HIV-1?

Journal of Acquired Immune Deficiency Syndromes

Volumn 25, Issue 5, 2000, Pages 398-402

  Dorman, Karin S ^a   Kaplan, Andrew H ^b   Lange, Kenneth ^a,c   Sinsheimer, Janet S ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anti retroviral therapy; HIV 1; Latent pool; Mathematical model; Resistance mutation; Structured treatment interruptions; Viral rebound

Indexed keywords

ANTIRETROVIRUS AGENT;

ARTICLE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LATENT PERIOD; MATHEMATICAL MODEL; NONHUMAN; PATIENT COMPLIANCE; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; VIRUS LOAD; VIRUS MUTATION; VIRUS REPLICATION;

EID: 0034671704     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200012150-00003     Document Type: Article

References (20)

1. Protease inhibitors: Resistance, cross-resistance, fitness and the choice of initial and salvage therapies
2. Constant mean viral copy number per infected cell in tissues regardless of high, low, or undetectable plasma HIV RNA
3. Is interruption of HIV therapy always harmful?
4. Mathematical analysis of antiretroviral therapy aimed at HIV-1 eradication or maintenance of low viral loads
5. Mathematical analysis of HIV-1 dynamics in vivo
6. HIV-1 dynamics in vivo: Virion clearance rate, infected cell life-span, and viral generation time
7. Decay characteristics of HIV-1-infected compartments during combination therapy
8. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection
9. Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1
10. Rate of HIV-1 RNA rebound upon stopping antiretroviral therapy
11. HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment
12. Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy
13. Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression
14. Human immunodeficiency virus drug resistance testing: State of the art in genotypic and phenotypic testing of anitretrovirals
15. + T cells provide a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy
16. Genetic diversity and evolution of retroviruses
17. + T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy
18. T lymphocyte responses in HIV-1 infection: Implications for vaccine development